These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23408017)

  • 21. Fractures related to bone fragility: prevention First-choice treatments.
    Prescrire Int; 2017 Apr; 26(181):103-106. PubMed ID: 30730663
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion.
    Migliorini F; Colarossi G; Baroncini A; Eschweiler J; Tingart M; Maffulli N
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):105-119. PubMed ID: 33183112
    [No Abstract]   [Full Text] [Related]  

  • 23. Current controversies in clinical management of postmenopausal osteoporosis.
    Kerschan-Schindl K; Mikosch P; Obermayer-Pietsch B; Gasser RW; Dimai HP; Fahrleitner-Pammer A; Dobnig H; Roschger P; Preisinger E; Klaushofer K; Resch H; Pietschmann P
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):437-44. PubMed ID: 24838156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2024 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong.
    ; Ip TP; Lee CA; Lui TD; Wong RMY; Cheung CL; Chiu KCP; Chow SLE; Ho CF; Ho TC; Ho YA; Lee KK; Li HR; Mak KC; Ng KD; Ngai SLI; Wong CG; Wong SJ; Wong SH; Wong TW
    Hong Kong Med J; 2024 Apr; 30 Suppl 2():1-44. PubMed ID: 39113555
    [No Abstract]   [Full Text] [Related]  

  • 25. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
    Lehmann T; Aeberli D
    Osteoporos Int; 2017 Oct; 28(10):3067-3068. PubMed ID: 28589418
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacologic management of osteoporosis.
    Fontenot HB; Harris AL
    J Obstet Gynecol Neonatal Nurs; 2014; 43(2):236-45; quiz E20-1. PubMed ID: 24502394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects and management of denosumab discontinuation.
    Chapurlat R
    Joint Bone Spine; 2018 Oct; 85(5):515-517. PubMed ID: 29317292
    [No Abstract]   [Full Text] [Related]  

  • 28. NICE recommends new treatment option for osteoporosis after menopause.
    Mahase E
    BMJ; 2024 Aug; 386():q1769. PubMed ID: 39117437
    [No Abstract]   [Full Text] [Related]  

  • 29. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
    Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
    Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
    Capozzi A; Lello S; Pontecorvi A
    Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
    Zhou J; Ma X; Wang T; Zhai S
    Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abaloparatide for the treatment of postmenopausal osteoporosis.
    Pietrogrande L; Raimondo E
    Drugs Today (Barc); 2018 May; 54(5):293-303. PubMed ID: 29911694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New management options for osteoporosis with emphasis on SERMs.
    McClung MR
    Climacteric; 2015; 18 Suppl 2():56-61. PubMed ID: 26503459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACOG Practice Bulletin N. 129. Osteoporosis.
    Committee on Practice Bulletins-Gynecology, The American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2012 Sep; 120(3):718-34. PubMed ID: 22914492
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
    Meijer WM; Penning-van Beest FJ; Olson M; Herings RM
    Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of osteoporosis: current state of the art.
    Hamrick I; Schrager S; Nye AM
    Wien Med Wochenschr; 2015 Feb; 165(3-4):54-64. PubMed ID: 25502850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Celiac disease and bone health: is there a gap in the management of postmenopausal osteoporosis?
    Stuckey BGA; Mahoney LA; Dragovic S; Brown SJ
    Climacteric; 2020 Dec; 23(6):559-565. PubMed ID: 32960111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
    Jansen JP; Bergman GJ; Huels J; Olson M
    Semin Arthritis Rheum; 2011 Feb; 40(4):275-84.e1-2. PubMed ID: 20828791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.